|
Mortality and survival
|
18
|
8
|
15
|
6
|
3
|
2
|
NA
|
NA
|
|
Survival
|
2
| |
2
| |
0
| |
NA
| |
|
Overall survival
|
5
| |
3
| |
2
| |
NA
| |
|
Cause- (or disease) specific survival
|
6
| |
5
| |
1
| |
NA
| |
|
Relative survival
|
1
| |
1
| |
0
| |
NA
| |
|
Metastasis-free survival
|
2
| |
2
| |
0
| |
NA
| |
|
Progression-free survival
|
1
| |
1
| |
0
| |
NA
| |
|
Biochemical recurrence-free survival
|
1
| |
1
| |
0
| |
NA
| |
|
Outcomes relating to neoplasms
|
19
|
7
|
18
|
6
|
1
|
1
|
0
|
0
|
|
(Change in) prostate-specific antigen (PSA) levels
|
3
| |
3
| |
0
| |
0
| |
|
Measurable disease response
|
1
| |
1
| |
0
| |
0
| |
|
Time to progression
|
2
| |
2
| |
0
| |
0
| |
|
Disease progression/Progression rate
|
2
| |
2
| |
0
| |
0
| |
|
Progression-free probability
|
1
| |
1
| |
0
| |
0
| |
|
Development of metastases
|
1
| |
1
| |
0
| |
0
| |
|
Metastases-free probability
|
1
| |
1
| |
0
| |
0
| |
|
Symptomatic skeletal event
|
1
| |
0
| |
1
| |
0
| |
|
Local disease
|
1
| |
1
| |
0
| |
0
| |
|
Positive surgical margins
|
1
| |
1
| |
0
| |
0
| |
|
Response duration
|
1
| |
1
| |
0
| |
0
| |
|
Failure-free probability
|
1
| |
1
| |
0
| |
0
| |
|
Development of castration-resistant disease
|
1
| |
1
| |
0
| |
0
| |
|
Treatment failure
|
2
| |
2
| |
0
| |
0
| |
|
Renal and urinary outcomes
|
13
|
6
|
8
|
3
|
3
|
2
|
2
|
1
|
|
Urinary incontinence
|
4
| |
2
| |
1
| |
1
| |
|
Urinary obstruction/irritation
|
3
| |
1
| |
1
| |
1
| |
|
Urinary symptoms
|
1
| |
0
| |
1
| |
0
| |
|
Voiding behaviour
|
1
| |
1
| |
0
| |
0
| |
|
Haematuria
|
1
| |
1
| |
0
| |
0
| |
|
Pelvic pain
|
1
| |
1
| |
0
| |
0
| |
|
Lymphedema
|
1
| |
1
| |
0
| |
0
| |
|
Urinary functioning
|
1
| |
1
| |
0
| |
0
| |
|
Gastrointestinal outcomes
|
6
|
5
|
3
|
2
|
2
|
2
|
1
|
1
|
|
Bowel symptoms
|
3
| |
0
| |
2
| |
1
| |
|
Faecal incontinence
|
1
| |
1
| |
0
| |
0
| |
|
Bowel functioning
|
1
| |
1
| |
0
| |
0
| |
|
Diarrhoea
|
1
| |
1
| |
0
| |
0
| |
|
Endocrine outcomes
|
3
|
3
|
0
|
0
|
2
|
2
|
1
|
1
|
|
Hormonal symptoms
|
3
| |
0
| |
2
| |
1
| |
|
Reproductive system outcomes
|
6
|
6
|
3
|
3
|
2
|
2
|
1
|
1
|
|
Erectile/sexual function
|
2
| |
2
| |
0
| |
0
| |
|
Erectile/sexual dysfunction (impotence)
|
3
| |
1
| |
1
| |
1
| |
|
Sexual symptoms
|
1
| |
0
| |
1
| |
0
| |
|
General outcomes
|
8
|
3
|
3
|
1
|
3
|
1
|
2
|
1
|
|
Pain
|
2
| |
0
| |
1
| |
1
| |
|
Fatigue
|
2
| |
0
| |
1
| |
1
| |
|
Bone pain
|
1
| |
1
| |
0
| |
0
| |
|
Weight loss
|
1
| |
1
| |
0
| |
0
| |
|
Anaemia
|
1
| |
1
| |
0
| |
0
| |
|
Performance status
|
1
| |
0
| |
1
| |
0
| |
|
Physical functioning
|
3
|
3
|
1
|
1
|
1
|
1
|
1
|
1
|
|
Physical wellbeing/functioning
|
3
| |
1
| |
1
| |
1
| |
|
Emotional functioning/wellbeing
|
4
|
4
|
2
|
2
|
1
|
1
|
1
|
1
|
|
Mental/emotional wellbeing/functioning
|
4
| |
2
| |
1
| |
1
| |
|
Social functioning
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
Social functioning
|
1
| |
1
| |
0
| |
0
| |
|
Role functioning
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
Role functioning
|
1
| |
1
| |
0
| |
0
| |
|
Global quality of life
|
6
|
6
|
6
|
6
|
0
|
0
|
0
|
0
|
|
Quality of life
|
6
| |
6
| |
0
| |
0
| |
|
Economic outcomes
|
2
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
|
Cost-effectiveness
|
1
| |
1
| |
0
| |
0
| |
|
Costs
|
1
| |
1
| |
0
| |
0
| |
|
Need for intervention
|
4
|
2
|
2
|
1
|
2
|
1
|
0
|
0
|
|
Need for salvage therapy
|
1
| |
1
| |
0
| |
0
| |
|
Need for curative treatment
|
1
| |
1
| |
0
| |
0
| |
|
Need for pain medication
|
1
| |
0
| |
1
| |
0
| |
|
Procedures need for local progression
|
1
| |
0
| |
1
| |
0
| |
|
Delivery of care
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
Time to treatment failure
|
1
| |
1
| |
0
| |
0
| |
|
Adverse events/effects
|
8
|
6
|
6
|
4
|
2
|
2
|
0
|
0
|
|
Adverse events
|
3
| |
2
| |
1
| |
0
| |
|
Perioperative deaths
|
1
| |
1
| |
0
| |
0
| |
|
Thromboembolic disease
|
1
| |
1
| |
0
| |
0
| |
|
Bothersome or symptomatic urethral or anastomotic stricture
|
1
| |
1
| |
0
| |
0
| |
|
Side-effects of hormonal therapy
|
1
| |
1
| |
0
| |
0
| |
|
Major systemic therapy effects
|
1
| |
0
| |
1
| |
0
| |
|
Total
|
103
| |
72
| |
22
| |
9
| |
